TAM
LTRN icon

Tucker Asset Management’s Lantern Pharma LTRN Stock Holding History

Tucker Asset Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,500
Closed -$101K – 1747
2024
Q1 		$101K Buy
+11,500
New +$61.4K 0.02% 279

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Tucker Asset Management's LTRN Position: Q2 2024 in Review

Tucker Asset Management sold out of Lantern Pharma (LTRN) in Q2 2024, closing a stake of 11,500 shares — an estimated $101K sold.

Tucker Asset Management first reported a position in LTRN in Q1 2024 and held it in 1 quarter. The position peaked at $101K in Q1 2024. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2024.

  • Tucker Asset Management reported no remaining Lantern Pharma position as of Q2 2024 after selling out during the quarter.
  • Tucker Asset Management sold 11,500 Lantern Pharma shares in Q2 2024, an estimated $101K.
  • Tucker Asset Management first reported a position in Lantern Pharma in Q1 2024 and held it in 1 quarter.
  • Tucker Asset Management's Lantern Pharma position peaked at $101K in Q1 2024.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2024.

Based on Tucker Asset Management's 13F filing for Q2 2024, filed 9 Aug 2024.